Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group (NYSE: STVN) introduced Deora™, a proprietary, multi-use, fixed-dose pen injector for subcutaneous delivery in therapies such as diabetes and weight management, including incretin-based treatments.
Deora features an intuitive pull-push mechanism, supports fixed-dose volumes up to 0.75 mL, works with standard 1.5 mL and 3 mL cartridges, and is designed for scalable manufacturing and integration into existing pharmaceutical supply chains.
Stevanato Group (NYSE: STVN) announced that all resolutions at its May 26, 2026 Ordinary and Extraordinary Shareholders’ Meeting were approved.
Key items included approval of 2025 financial statements, a EUR 0.054 dividend per share, board and auditor appointments, a new treasury share authorization, and by-law amendments.
Stevanato Group (NYSE: STVN) reported Q1 FY2026 revenue of €273.6M, up 7% (10% constant currency), with 47% of sales from high-value solutions. Adjusted EBITDA was €65.5M (margin 23.9%); diluted EPS €0.10 and adjusted diluted EPS €0.11. Fiscal 2026 guidance is maintained.
Stevanato Group (NYSE: STVN) will participate in three investor conferences: Bank of America Global Healthcare on May 12, 2026 at 8:00 a.m. PT in Las Vegas; William Blair Growth Stock on June 2, 2026 at 2:40–3:10 p.m. CT in Chicago; and Jefferies Healthcare on June 4, 2026 at 9:55–10:25 a.m. EDT in New York.
Live webcasts will be available via the company Investors page and replays will remain online for approximately 90 days after each event.
Stevanato Group (NYSE: STVN) will report first quarter 2026 financial results on May 7, 2026 at 6:30 a.m. EDT, with a conference call and live webcast at 8:30 a.m. EDT the same day.
Management will use a slide presentation available the morning of the call on the company's Investor Relations site. Pre-registration provides a passcode and PIN; international and US dial-in numbers are provided. The webcast will be archived for three months.
Stevanato Group (NYSE: STVN) will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on Tuesday, March 17 and Wednesday, March 18, 2026. The company will present on March 17 at 9:45-10:20 a.m. ET.
A live webcast will be available on the company’s Investors page, with a replay accessible for approximately 90 days after the event.
Stevanato Group (NYSE: STVN) reported FY2025 revenue of €1.186 billion (+7% reported; +9% constant currency) and record demand for high-value solutions. Gross profit margin expanded to 29.0% and adjusted EBITDA margin to 25.1%. Diluted EPS rose 19% to €0.51.
The company logged Q4 revenue of €346.5 million, Q4 high-value solutions of €171.4 million (49% of revenue), cash of €130.6 million, net debt of €337.7 million, and reported positive free cash flow of €18.4 million for 2025. Fiscal 2026 guidance: revenue €1.26–1.29 billion; adjusted EBITDA €331.8–346.9 million; adjusted diluted EPS €0.59–0.63.
Stevanato Group (NYSE: STVN) will report fourth quarter and fiscal year 2025 results on Wednesday, March 4, 2026 with results issued at 6:30 a.m. ET and a conference call and webcast at 8:30 a.m. ET. The company said a slide presentation will be posted the morning of the call and the webcast will be archived for three months.
Stevanato Group (NYSE: STVN) reported Q3 2025 revenue of €303.2M, up 9% YoY (11% constant currency), with record high-value solutions at €147.9M (49% of revenue).
Gross profit margin rose 240 bps to 29.2%, adjusted EBITDA margin improved 280 bps to 25.7%, and adjusted diluted EPS was €0.14. BDS segment revenue grew 14% to €266.7M, while Engineering revenue fell 19% to €36.4M. Cash was €113.3M and net debt €333M; Q3 free cash flow was €0.3M.
The company maintained fiscal 2025 guidance: revenue €1.160–1.190B, adjusted EBITDA €288.5–301.8M, and adjusted diluted EPS €0.50–0.54.
Stevanato Group (NYSE: STVN) will participate in two investor conferences in mid-November 2025. The company will present at The 7th Annual Wolfe Research Healthcare Conference in New York on Monday, November 17, 2025 at 8:40 a.m. ET and at The Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:00 a.m. GMT.
A live webcast of each presentation will be available on the company website under Investors, with replays accessible for approximately 90 days after each event.